Oral weight loss pills could claim half of GLP-1 market by 2030 says Structure Therapeutics CEO
Structure Therapeutics CEO Raymond Stevens projects oral pills will claim half the GLP-1 market by 2030. This shift is driven by primary care physician demand.
Insights:
The pharmaceutical landscape for weight-loss treatments is poised for a major structural transformation as oral medications challenge the dominance of injectables. Raymond Stevens raymond stevens, the chief executive of Structure Therapeutics Inc. , recently projected that oral GLP-1 pills could account for as much as half of the total market by 2030. This forecast is based on an estimated global population of one to three billion overweight or obese individuals who may seek more convenient treatment options.
Historically, the GLP-1 market has been defined by injectable formulations manufactured by major players such as Novo Nordisk A/S and Eli Lilly and Company . These treatments have traditionally been prescribed by specialists, including endocrinologists and obesity medicine experts. However, the market is currently experiencing a shift as primary care physicians begin to take a more active role in managing weight-loss treatments for their patients.
